Abstract 115P
Background
Colorectal cancer is in fourth place due to mortality worldwide. In order to improve the diagnosis of colorectal cancer, immunohistochemical studies are becoming increasingly popular. The available literature contains a number of publications devoted to the study of the prognostic value of the expression of various biomarkers. However, the value of expression levels of the proliferation marker Ki-67 in colorectal cancer remains poorly understood. In this regard, the purpose of our study was to study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer.
Methods
To study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer, we examined 201 patients with colorectal cancer who were undergoing surgical treatment in combination with chemotherapy.
Results
A study of the proliferative activity of tumor glandular epithelial cells using patient Ki-67 proliferation marker showed that low or medium expression level (≤ 30%) was observed in 138 (68.9%) patients, while high (> 30%) - in 63 patients (31.1%). Binary logistic regression made it possible to establish links between the expression level of Ki-67 and the tumor stage, the presence of metastases in regional lymph nodes, the presence of distant metastases and the degree of tumor differentiation. In particular, patients with stage II, III, and IV stages of cancer had a higher chance of having a high level of Ki-67 expression than patients with stage I disease — 2.63, 3.16, and 3.97 times, respectively. The presence of 4 or more regional lymph nodes (N2) was accompanied by higher chances (6.6 times) to have a high level of expression of Ki-67, and the presence of distant metastases (M1) - by 1.92 times. Patients with low-differentiated cancer had a 5.1- times higher chance of being in the group with a high level of Ki-67 expression than patients with highly differentiated cancer.
Conclusions
The results of the research on finding the most informative and effective methods for predicting and diagnosing colorectal cancer among residents of the studied region will allow developing and introducing methods for complex primary and secondary prevention.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract